Compare Abeona Therapeutics Inc (ABEO) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs J B Hunt Transport Services Inc — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while J B Hunt Transport Services Inc trades at $273.15 (market cap $25.93B). The key difference: J B Hunt Transport Services Inc is far larger — about 69.5× Abeona Therapeutics Inc's market cap, and J B Hunt Transport Services Inc pays a 0.65% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | JBHT | |
|---|---|---|
Market Cap | $373.32M | $25.93B |
Sector | Health | Industrials |
52-Week High | $7.23 | $290.07 |
52-Week Low | $4.17 | $130.65 |
Enterprise Value | $228.22M | $27.23B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
JBHT trades at $275.00, down 3.79% over 24 hours, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported revenue of $12.00 billion in 2025 with a net income margin of 5.13%, and has beaten earnings estimates for the last three quarters. Recent news highlights its participation in industry conferences and positive analyst coverage amid a improving freight scenario.
The outlook for JBHT is supported by consistent earnings beats and a favorable analyst consensus, though high valuation ratios and exposure to freight market cyclicality present risks. Upside potential exists if the company maintains operational efficiency and capitalizes on industry tailwinds, but investors should weigh elevated P/E and P/B multiples against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
